Search

Your search keyword '"Schetelig, Johannes"' showing total 32 results
Start Over Author "Schetelig, Johannes" Publication Year Range This year
32 results on '"Schetelig, Johannes"'

1. How risky is a second allogeneic stem cell transplantation?

Author

Penack, Olaf, Abouqateb, Mouad, Peczynski, Christophe, Boreland, William, Kröger, Nicolaus, Zeiser, Robert, Ciceri, Fabio, Schroeder, Thomas, Dreger, Peter, Passweg, Jakob, Schetelig, Johannes, Stelljes, Matthias, Blau, Igor Wolfgang, Franke, Georg-Nikolaus, Riesner, Katarina, Schoemans, Hélène, Moiseev, Ivan, and Peric, Zinaida

Published
2024
Full Text
View/download PDF

2. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Author

Guièze, Romain, Eikema, Diderik-Jan, Koster, Linda, Schetelig, Johannes, Sengeloev, Henrik, Passweg, Jakob, Finke, Jürgen, Arat, Mutlu, Broers, Annoek E. C., Stölzel, Friedrich, Byrne, Jenny, Castilla-Llorente, Cristina, Dreger, Peter, Eder, Matthias, Gedde-Dahl, Tobias, Kröger, Nicolaus, Ribera Santasusana, Josep Maria, Richardson, Deborah, Rambaldi, Alessandro, Yañez, Lucrecia, Van Gelder, Michel, Drozd-Sokolowska, Joanna, Raj, Kavita, Yakoub-Agha, Ibrahim, Tournilhac, Olivier, and McLornan, Donal P.

Published
2024
Full Text
View/download PDF

3. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

Author

Sureda, Anna, Carpenter, Paul A., Bacigalupo, Andrea, Bhatt, Vijaya Raj, de la Fuente, Josu, Ho, Aloysius, Kean, Leslie, Lee, Jong Wook, Sánchez-Ortega, Isabel, Savani, Bipin N., Schetelig, Johannes, Stadtmauer, Edward A., Takahashi, Yoshiyuki, Atsuta, Yoshiko, Koreth, John, Kröger, Nicolaus, Ljungman, Per, Okamoto, Shinichiro, Popat, Uday, Soiffer, Robert, Stefanski, Heather E., and Kharfan-Dabaja, Mohamed A.

Published
2024
Full Text
View/download PDF

4. Chronic Lymphocytic Leukemia

Author

Schetelig, Johannes, Dreger, Peter, Sureda, Anna, editor, Corbacioglu, Selim, editor, Greco, Raffaella, editor, Kröger, Nicolaus, editor, and Carreras, Enric, editor

Published
2024
Full Text
View/download PDF

5. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

Author

Al-Sawaf, Othman, Ligtvoet, Rudy, Robrecht, Sandra, Stumpf, Janina, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Boettcher, Sebastian, Mikusko, Martin, Ritgen, Matthias, Schetelig, Johannes, von Tresckow, Julia, Vehling-Kaiser, Ursula, Gaska, Tobias, Wendtner, Clemens Martin, Chapuy, Bjoern, Fischer, Kirsten, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Staber, Philipp, Niemann, Carsten, Hallek, Michael, and Eichhorst, Barbara

Published
2024
Full Text
View/download PDF

6. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Author

Fürstenau, Moritz, Giza, Adam, Weiss, Jonathan, Kleinert, Fanni, Robrecht, Sandra, Franzen, Fabian, Stumpf, Janina, Langerbeins, Petra, Al-Sawaf, Othman, Simon, Florian, Fink, Anna-Maria, Schneider, Christof, Tausch, Eugen, Schetelig, Johannes, Dreger, Peter, Böttcher, Sebastian, Fischer, Kirsten, Kreuzer, Karl-Anton, Ritgen, Matthias, Schilhabel, Anke, Brüggemann, Monika, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael, and Cramer, Paula

Published
2024
Full Text
View/download PDF

9. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

Author

Alakel, Nael, Albring, Jörn, Berdel, Wolfgang E., Bethge, Wolfgang, Bornhäuser, Martin, Bug, Gesine, Buhl, Christoph, Call, Simon, Crysandt, Martina, Egger-Heidrich, Katharina, Eßeling, Eva, Faul, Christoph, Franke, Georg-Nikolaus, Georgi, Julia-Annabell, Glück-Wolf, Julia, Groth, Christoph, Hauptrock, Beate, Heidenreich, Daniela, Janjetovic, Snjezana, Jost, Edgar, Kaufmann, Martin, Kindler, Thomas, Klein, Stefan A., Krause, Stefan W., Kreil, Sebastian, Kretschmann, Theresa, Kunadt, Desiree, Lang, Fabian, Lenz, Georg, Martin, Sonja, Marx, Julia, Middeke, Jan-Moritz, Mikesch, Jan-Henrik, Müller, Lutz P., Müller, Nadine, Niederland, Judith, Parmentier, Stefani, Petzold, Kathrin, Platzbecker, Uwe, Rank, Andreas, Reicherts, Christian, Röllig, Christoph, Rösler, Wolf, Schäfer-Eckart, Kerstin, Schaffrath, Judith, Schaich, Markus, Schetelig, Johannes, Schliemann, Christoph, Schmid, Christoph, Schneidawind, Dominik, Schubert, Jörg, Serve, Hubert, Sockel, Katja, Steffen, Björn, Stelljes, Matthias, Teipel, Raphael, von Bonin, Malte, Wagner-Drouet, Eva, Wass, Maxi, Wendelin, Knut, Middeke, Jan Moritz, Wagner-Drouet, Eva-Maria, Müller, Lutz P, Krause, Stefan W, Klein, Stefan A, Baldauf, Henning, Stölzel, Friedrich, Petzold, Cathleen, Kriege, Oliver, Berdel, Wolfgang E, Ehninger, Gerhard, and Schmidt, Alexander H

Published
2024
Full Text
View/download PDF

10. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Author

Stilgenbauer, Stephan, Tausch, Eugen, Roberts, Andrew W., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Hillmen, Peter, Schneider, Christof, Schetelig, Johannes, Böttcher, Sebastian, Kater, Arnon P., Jiang, Yanwen, Boyer, Michelle, Popovic, Relja, Ghanim, Majd T., Moran, Michael, Sinai, Wendy J., Wang, Xifeng, Mukherjee, Nabanita, Chyla, Brenda, Wierda, William G., and Seymour, John F.

Published
2024
Full Text
View/download PDF

12. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML

Author

Fein, Joshua A., Shouval, Roni, Krieger, Elizabeth, Spellman, Stephen R., Wang, Tao, Baldauf, Henning, Fleischhauer, Katharina, Kröger, Nicolaus, Horowitz, Mary, Maiers, Martin, Miller, Jeffrey S, Mohty, Mohamad, Nagler, Arnon, Weisdorf, Daniel, Malmberg, Karl-Johan, Toor, Amir A., Schetelig, Johannes, Romee, Rizwan, and Koreth, John

Published
2024
Full Text
View/download PDF

13. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Author

Jost, Edgar, Schmid, Christoph, Baurmann, Herrad, Blau, Igor, Holderried, Tobias, Hertenstein, Bernd, Hänel, Mathias, Bornhäuser, Martin, Neidlinger, Helga, Kobbe, Guido, Winkler, Julia, Schroeder, Thomas, Bug, Gesine, Hopfer, Olaf, Finke, Jürgen, Hasenkamp, Justin, Krüger, William, Müller, Lutz, Kröger, Nikolaus, Eder, Matthias, Luft, Thomas, Hilgendorf, Inken, Ringhoffer, Mark, Stölzel, Friedrich, Scheid, Christoph, Platzbecker, Uwe, Wortmann, Friederike, Heinicke, Thomas, Wagner, Eva, Klein, Stefan, Burchert, Andreas, Tischer, Johanna, Stelljes, Matthias, Schäfer-Eckart, Kerstin, Wolff, Daniel, Junghanss, Christian, Ritter, Markus, Kaufmann, Martin, Bethge, Wolfgang, Mytilineos, Joannis, Einsel, Hermann, Sockel, Katja, Neu, Annika, Goeckenjan, Maren, Ditschkowski, Markus, Kröger, Nicolaus, Ayuk, Francis A., Stoelzel, Friedrich, Middeke, Jan Moritz, Bertz, Hartmut, Beverungen, David, von Bonin, Malte, Egger-Heidrich, Katharina, Heberling, Lisa, Trautmann-Grill, Karolin, Teipel, Raphael, Fraccaroli, Alessia, Fante, Matthias, Scheid, Christof, Holtick, Udo, Blau, Igor Wolfgang, Wulf, Gerald, Schwerdtfeger, Rainer, Kaun, Stephan, Winter, Susann, Theuser, Catrin, Beyersmann, Jan, Bornhaeuser, Martin, Schmeller, Sandra, and Schetelig, Johannes

Published
2024
Full Text
View/download PDF

14. Supplementary Tables 1 from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study

Author

Bazarbachi, Ali, primary, Labopin, Myriam, primary, Moukalled, Nour, primary, Kröger, Nicolaus, primary, Rautenberg, Christina, primary, Schetelig, Johannes, primary, Finke, Jürgen, primary, Blau, Igor Wolfgang, primary, Blaise, Didier, primary, Stelljes, Matthias, primary, Eder, Matthias, primary, Platzbecker, Uwe, primary, Dreger, Peter, primary, Bethge, Wolfgang, primary, Tischer, Johanna, primary, Burns, David, primary, Sengeloev, Henrik, primary, Brissot, Eolia, primary, Giebel, Sebastian, primary, Nagler, Arnon, primary, Ciceri, Fabio, primary, and Mohty, Mohamad, primary

Published
2024
Full Text
View/download PDF

15. Data from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study

Author

Bazarbachi, Ali, primary, Labopin, Myriam, primary, Moukalled, Nour, primary, Kröger, Nicolaus, primary, Rautenberg, Christina, primary, Schetelig, Johannes, primary, Finke, Jürgen, primary, Blau, Igor Wolfgang, primary, Blaise, Didier, primary, Stelljes, Matthias, primary, Eder, Matthias, primary, Platzbecker, Uwe, primary, Dreger, Peter, primary, Bethge, Wolfgang, primary, Tischer, Johanna, primary, Burns, David, primary, Sengeloev, Henrik, primary, Brissot, Eolia, primary, Giebel, Sebastian, primary, Nagler, Arnon, primary, Ciceri, Fabio, primary, and Mohty, Mohamad, primary

Published
2024
Full Text
View/download PDF

16. Supplementary Figure 1 from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study

Author

Bazarbachi, Ali, primary, Labopin, Myriam, primary, Moukalled, Nour, primary, Kröger, Nicolaus, primary, Rautenberg, Christina, primary, Schetelig, Johannes, primary, Finke, Jürgen, primary, Blau, Igor Wolfgang, primary, Blaise, Didier, primary, Stelljes, Matthias, primary, Eder, Matthias, primary, Platzbecker, Uwe, primary, Dreger, Peter, primary, Bethge, Wolfgang, primary, Tischer, Johanna, primary, Burns, David, primary, Sengeloev, Henrik, primary, Brissot, Eolia, primary, Giebel, Sebastian, primary, Nagler, Arnon, primary, Ciceri, Fabio, primary, and Mohty, Mohamad, primary

Published
2024
Full Text
View/download PDF

17. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight

Author

Schetelig, Johannes, primary, Baldauf, Henning, additional, Heidenreich, Falk, additional, Hoogenboom, Jorinde D., additional, Spellman, Stephen R., additional, Kulagin, Alexander, additional, Schroeder, Thomas, additional, Sengeloev, Henrik, additional, Dreger, Peter, additional, Forcade, Edouard, additional, Vydra, Jan, additional, Wagner-Drouet, Eva Maria, additional, Choi, Goda, additional, Paneesha, Shankara, additional, Miranda, Nuno A. A., additional, Tanase, Alina, additional, de Wreede, Liesbeth C., additional, Lange, Vinzenz, additional, Schmidt, Alexander H., additional, Sauter, Jürgen, additional, Fein, Joshua A., additional, Bolon, Yung-Tsi, additional, He, Meilun, additional, Marsh, Steven G. E., additional, Gadalla, Shahinaz M., additional, Paczesny, Sophie, additional, Ruggeri, Annalisa, additional, Chabannon, Christian, additional, and Fleischhauer, Katharina, additional

Published
2024
Full Text
View/download PDF

18. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

Author

Eckardt, Jan-Niklas, primary, Hahn, Waldemar, additional, Röllig, Christoph, additional, Stasik, Sebastian, additional, Platzbecker, Uwe, additional, Müller-Tidow, Carsten, additional, Serve, Hubert, additional, Baldus, Claudia D., additional, Schliemann, Christoph, additional, Schäfer-Eckart, Kerstin, additional, Hanoun, Maher, additional, Kaufmann, Martin, additional, Burchert, Andreas, additional, Thiede, Christian, additional, Schetelig, Johannes, additional, Sedlmayr, Martin, additional, Bornhäuser, Martin, additional, Wolfien, Markus, additional, and Middeke, Jan Moritz, additional

Published
2024
Full Text
View/download PDF

19. Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Long Term Follow up of BMT CTN 1301 Progress II Trial

Author

Pasquini, Marcelo C., primary, Soiffer, Robert, additional, Logan, Brent, additional, Kaur, Manmeet, additional, Devine, Steven M., additional, Geller, Nancy, additional, Giralt, Sergio A., additional, Heslop, Helen E., additional, Horowitz, Mary M., additional, Litzow, Mark R., additional, Mendizabal, Adam, additional, Muffly, Lori S, additional, Nemecek, Eneida, additional, O'Donnell, Lynn C., additional, Schetelig, Johannes, additional, Shune, Leyla, additional, Solomon, Scott R., additional, Vasu, Sumithira, additional, Ho, Dr. Vincent T., additional, Perales, Miguel-Angel, additional, and Luznik, Leo, additional

Published
2024
Full Text
View/download PDF

20. Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies

Author

Schulz, Felicitas, primary, Jäger, Paul, additional, Tischer, Johanna, additional, Fraccaroli, Alessia, additional, Bug, Gesine, additional, Hausmann, Andreas, additional, Baermann, Ben-Niklas, additional, Tressin, Patrick, additional, Hoelscher, Alexander, additional, Kasprzak, Annika, additional, Nachtkamp, Kathrin, additional, Schetelig, Johannes, additional, Hilgendorf, Inken, additional, Germing, Ulrich, additional, Dietrich, Sascha, additional, and Kobbe, Guido, additional

Published
2024
Full Text
View/download PDF

21. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

Author

Stelljes, Matthias, Middeke, Jan Moritz, Bug, Gesine, Wagner-Drouet, Eva-Maria, Müller, Lutz P, Schmid, Christoph, Krause, Stefan W, Bethge, Wolfgang, Jost, Edgar, Platzbecker, Uwe, Klein, Stefan A, Schubert, Jörg, Niederland, Judith, Kaufmann, Martin, Schäfer-Eckart, Kerstin, Schaich, Markus, Baldauf, Henning, Stölzel, Friedrich, Petzold, Cathleen, Röllig, Christoph, Alakel, Nael, Steffen, Björn, Hauptrock, Beate, Schliemann, Christoph, Sockel, Katja, Lang, Fabian, Kriege, Oliver, Schaffrath, Judith, Reicherts, Christian, Berdel, Wolfgang E, Serve, Hubert, Ehninger, Gerhard, Schmidt, Alexander H, Bornhäuser, Martin, Mikesch, Jan-Henrik, Schetelig, Johannes, Alakel, Nael, Albring, Jörn, Berdel, Wolfgang E., Bethge, Wolfgang, Bornhäuser, Martin, Bug, Gesine, Buhl, Christoph, Call, Simon, Crysandt, Martina, Egger-Heidrich, Katharina, Eßeling, Eva, Faul, Christoph, Franke, Georg-Nikolaus, Georgi, Julia-Annabell, Glück-Wolf, Julia, Groth, Christoph, Hauptrock, Beate, Heidenreich, Daniela, Janjetovic, Snjezana, Jost, Edgar, Kaufmann, Martin, Kindler, Thomas, Klein, Stefan A., Krause, Stefan W., Kreil, Sebastian, Kretschmann, Theresa, Kunadt, Desiree, Lang, Fabian, Lenz, Georg, Martin, Sonja, Marx, Julia, Middeke, Jan-Moritz, Mikesch, Jan-Henrik, Müller, Lutz P., Müller, Nadine, Niederland, Judith, Parmentier, Stefani, Petzold, Kathrin, Platzbecker, Uwe, Rank, Andreas, Reicherts, Christian, Röllig, Christoph, Rösler, Wolf, Schäfer-Eckart, Kerstin, Schaffrath, Judith, Schaich, Markus, Schetelig, Johannes, Schliemann, Christoph, Schmid, Christoph, Schneidawind, Dominik, Schubert, Jörg, Serve, Hubert, Sockel, Katja, Steffen, Björn, Stelljes, Matthias, Teipel, Raphael, von Bonin, Malte, Wagner-Drouet, Eva, Wass, Maxi, and Wendelin, Knut

Abstract

Whether high-dose cytarabine-based salvage chemotherapy, administered to induce complete remission in patients with poor responsive or relapsed acute myeloid leukaemia scheduled for allogeneic haematopoietic stem-cell transplantation (HSCT) after intensive conditioning confers a survival advantage, is unclear.

Published
2024
Full Text
View/download PDF

24. Autoren

Author

Aguinarte, Lukas J., Ahrens, Marit, Armbrust, Robert, Becker, Sven, Bergmann, Lothar, Bojunga, Jörg, Bug, Gesine, Büntzel, Jens, Burger, Michael, Chromik, Jörg, Chun, Felix K.-H., Dumoulin, Franz Ludwig, Dreyling, Martin, Ebert, Matthias, El-Balat, Ahmed, Ellinger, Jörg, Elsner, Susanne, Enßle, Julius C., Fottner, Christian, Gökbuget, Nicola, Götze, Thorsten Oliver, Halbsguth, Teresa, Hartmann, Sylvia, Höh, Benedikt, Hohenberger, Peter, Hübner, Joachim, Hübner, Jutta, Isfort, Susanne, Kasper, Bernd, Kestler, Angelika, Kleemann, Johannes, Kluth, Luis A., Köhler, Viktoria F., Kollmar, Otto, Lang, Fabian, Makowka, Philipp, Mallmann-Gottschalk, Nina, Mandel, Philipp, Maurer, Gabriele D., Mayer, Arnulf, Meissner, Markus, Menge, Franka, Middeke, Jan Moritz, Miesbach, Wolfgang, Möhler, Markus, Möbus, Volker, Müller, Stefan C., Nauck, Friedemann, Oellerich, Thomas, Özistanbullu, Deniz, Pox, Christian, Richter, Konrad Klaus, Scheich, Sebastian, Schetelig, Johannes, Schnürch, Hans-Georg, Sehouli, Jalid, Seifart, Ulf, Serve, Hubert, Seufferlein, Thomas, Shaid, Shabnam, Soysal, Savas D., Staubitz, Julia I., Steffen, Björn, Steinbach, Joachim P., Stratmann, Jan A., Tsoukakis, Ioannis, Ullrich, Evelyn, Vehreschild, Janne, Metzler, Ivana von, Wolff, Michael von, Voß, Martin, Wagner, Sebastian, Weber, Matthias M., Weber, Sarah, Wege, Henning, Weis, Joachim, Welte, Maria-Noemi, Wenzel, Mike, Wölber, Linn, Wolf, Timo, Zimpel, Carolin, Zurmeyer, David, and Zurmeyer, Sarah

Published
2024
Full Text
View/download PDF

26. Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

Author

Sureda, Anna, Carpenter, Paul A., Bacigalupo, Andrea, Bhatt, Vijaya Raj, de la Fuente, Josu, Ho, Aloysius, Kean, Leslie, Lee, Jong Wook, Sánchez-Ortega, Isabel, Savani, Bipin N., Schetelig, Johannes, Stadtmauer, Edward A., Takahashi, Yoshiyuki, Atsuta, Yoshiko, Koreth, John, Kröger, Nicolaus, Ljungman, Per, Okamoto, Shinichiro, Popat, Uday, Soiffer, Robert, Stefanski, Heather E., and Kharfan-Dabaja, Mohamed A.

Published
2024
Full Text
View/download PDF

27. Hope for Motherhood: Pregnancy After Allogeneic Hematopoietic Cell Transplantation – a National Multicenter Study

Author

Sockel, Katja, Neu, Annika, Goeckenjan, Maren, Ditschkowski, Markus, Hilgendorf, Inken, Kröger, Nicolaus, Ayuk, Francis A., Stoelzel, Friedrich, Middeke, Jan Moritz, Eder, Matthias, Bethge, Wolfgang, Finke, Jürgen, Bertz, Hartmut, Kobbe, Guido, Kaufmann, Martin, Platzbecker, Uwe, Beverungen, David, Schmid, Christoph, von Bonin, Malte, Egger-Heidrich, Katharina, Heberling, Lisa, Trautmann-Grill, Karolin, Teipel, Raphael, Bug, Gesine, Tischer, Johanna, Fraccaroli, Alessia, Fante, Matthias, Wolff, Daniel, Luft, Thomas, Winkler, Julia, Schäfer-Eckart, Kerstin, Scheid, Christof, Holtick, Udo, Klein, Stefan, Blau, Igor Wolfgang, Burchert, Andreas, Wulf, Gerald, Hasenkamp, Justin, Schwerdtfeger, Rainer, Kaun, Stephan, Junghanss, Christian, Wortmann, Friederike, Winter, Susann, Neidlinger, Helga, Theuser, Catrin, Beyersmann, Jan, Bornhaeuser, Martin, Schmeller, Sandra, Schetelig, Johannes, Jost, Edgar, Schmid, Christoph, Baurmann, Herrad, Blau, Igor, Holderried, Tobias, Hertenstein, Bernd, Hänel, Mathias, Bornhäuser, Martin, Neidlinger, Helga, Kobbe, Guido, Winkler, Julia, Schroeder, Thomas, Bug, Gesine, Hopfer, Olaf, Finke, Jürgen, Hasenkamp, Justin, Krüger, William, Müller, Lutz, Kröger, Nikolaus, Eder, Matthias, Luft, Thomas, Hilgendorf, Inken, Ringhoffer, Mark, Stölzel, Friedrich, Scheid, Christoph, Platzbecker, Uwe, Wortmann, Friederike, Heinicke, Thomas, Wagner, Eva, Klein, Stefan, Burchert, Andreas, Tischer, Johanna, Stelljes, Matthias, Schäfer-Eckart, Kerstin, Wolff, Daniel, Junghanss, Christian, Ritter, Markus, Kaufmann, Martin, Bethge, Wolfgang, Mytilineos, Joannis, and Einsel, Hermann

Abstract

•Successful pregnancies are possible among female alloHCT recipients, although birth rate is more than six times lower than in the general population.•Key factors increasing the chance of motherhood were younger age at HCT, non-malignant disease, no TBI or dose <8Gy and RIC/NMA conditioning

Published
2024
Full Text
View/download PDF

28. Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

Author

Sellner, Leopold, Schetelig, Johannes, Koster, Linda, Choi, Goda, Blaise, Didier, Beelen, Dietrich, Schianca, Fabrizio Carnevale, Passweg, Jakob, Schanz, Urs, Gyan, Emmanuel, Sora, Federica, Kröger, Nicolaus, Wulf, Gerald. G., Van Gorkom, Gwendolyn, Mayer, Jiri, Orvain, Corentin, Bourhis, Jean Henri, Jindra, Pavel, Potter, Victoria, Zallio, Francesco, Vandenberghe, Elisabeth, Robinson, Stephen, Hayden, Patrick J., Yakoub-Agha, Ibrahim, Montoto, Silvia, and Dreger, Peter

Published
2024
Full Text
View/download PDF

29. Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes

Author

Camacho-Bydume, Christine, Wang, Tao, Sees, Jennifer A., Fernandez-Viña, Marcelo, Abid, Muhammad Bilal, Askar, Medhat, Beitinjaneh, Amer, Brown, Valerie, Castillo, Paul, Chhabra, Saurabh, Gadalla, Shahinaz M., Hsu, Jing-Mei, Kamoun, Malek, Lazaryan, Aleksandr, Nishihori, Taiga, Page, Kristin, Schetelig, Johannes, Fleischhauer, Katharina, Marsh, Steven G.E., Paczesny, Sophie, Spellman, Stephen R., Lee, Stephanie J., and Hsu, Katharine C.

Abstract

•HLA zygosity, supertypes, and expression are evaluated in post-transplant outcomes.•HLA-B62 supertype is associated with reduced transplant-related mortality.•HLA-B27 supertype is correlated with worse disease free-survival in acute myeloid leukemia.•No association exists between HLA zygosity or expression and transplant outcomes.

Published
2024
Full Text
View/download PDF

30. Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.

Author

Niederwieser D, Hasenclever D, Berdel WE, Biemond BJ, Al-Ali H, Chalandon Y, Van Gelder M, Junghanß C, Gahrton G, Hänel M, Hehlmann R, Heinicke T, Hochhaus A, Iacobelli S, Kooy RVM, Kröger N, Janssen J, Jentzsch M, Breywisch F, Mohty M, Masouridi-Levrat S, Ossenkoppele G, Passweg J, Pönisch W, Schetelig J, Schliemann C, Schwind S, Stelljes M, Verdonck LF, Vucinic V, Löwenberg B, and Cornelissen J

Abstract

Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in CR1 aged 60-75 years were registered and a donor search initiated. After one consolidation cycle, patients with a matched donor were randomized to HCT with fludarabine/lowdose total body irradiation and cyclosporine/mycophenolate mofetil immunosuppression or conventional non-HCT. Primary outcome was restricted mean leukemia-free survival (RM-LFS) up to five years. Between 2010 and 2017, 245 patients (median age 67 years) were registered at CR1. After one consolidation, 26.9% of patients failed inclusion criteria. Of the 179 (73%) patients still on study, 75.4% had an HLA identical donor. Ten ineligible patients were excluded, and 125 randomized to HCT (n=83) or non-HCT (n=42). The primary outcome RM-LFS up to 5 years was 24.5 months (95%CI:18.9-30.1) in the HCT and 15.6 months (95%CI:10.4-20.8) in the non-HCT arm (p=0.022) due to a decrease in cumulative relapse incidence from 91.1 (95%CI:80.7-100.0) after non-HCT to 37.8 (95%CI:27.2-48.4)% after HCT (p.

Published
2024
Full Text
View/download PDF

31. Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study.

Author

Bazarbachi A, Labopin M, Moukalled N, Kröger N, Rautenberg C, Schetelig J, Finke J, Blau IW, Blaise D, Stelljes M, Eder M, Platzbecker U, Dreger P, Bethge W, Tischer J, Burns D, Sengeloev H, Brissot E, Giebel S, Nagler A, Ciceri F, and Mohty M

Subjects
Humans, Aged, Female, Male, Aged, 80 and over, Treatment Outcome, Transplantation, Homologous, Follow-Up Studies, Graft vs Host Disease etiology, Graft vs Host Disease epidemiology, Transplantation Conditioning methods, Remission Induction, Retrospective Studies, Leukemia, Myeloid, Acute therapy, Leukemia, Myeloid, Acute mortality, Hematopoietic Stem Cell Transplantation methods, Hematopoietic Stem Cell Transplantation adverse effects
Abstract

Purpose: Acute myeloid leukemia (AML) is a disease of older patients. Progress in allogeneic hematopoietic cell transplantation (allo-HCT) allowed the delivery of allo-HCT to older patients. We assessed changes over time in transplant characteristics and outcomes in patients with AML ages 65 years and above., Patients and Methods: We identified 7,215 patients with AML (median age 68 years, range 65-80) allografted between 2000 and 2021 in first complete remission (CR1; 64%), second or subsequent remission (CR2+; 14%), or active disease (22%)., Results: Median follow-up was 40 months. The 3-year cumulative relapse incidence (RI) gradually and significantly decreased from 37% to 31%, then to 30% (P = 0.001) over the three time periods (2000-2009; 2010-2014; 2015-2021), whereas nonrelapse mortality (NRM) decreased from 31% and 31% to 27% (P = 0.003). The 3-year leukemia-free survival (LFS) and overall survival (OS) gradually and significantly improved from 32% to 38%, and then to 44% (P = 0.001) and from 37% to 42%, and then to 49% (P = 0.001), respectively. In multivariate analysis, significant improvement in the RI, LFS, and OS were noted after 2015, whereas NRM was not significantly affected. This improvement was observed regardless of disease status at transplant., Conclusions: In older patients with AML, we observed an impressive improvement over time in posttransplant outcomes, mostly attributed to decreased RI rather than decreased NRM, and regardless of disease status at transplant. These large-scale, real-world data can serve as a benchmark for future studies in this setting and indicate that the opportunity for transplant for the elderly should be mandatory and no longer an option., (©2024 American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

32. Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study.

Author

Weller JF, Lengerke C, Finke J, Schetelig J, Platzbecker U, Einsele H, Schroeder T, Faul C, Stelljes M, Dreger P, Blau IW, Wulf G, Tischer J, Scheid C, Elmaagacli A, Neidlinger H, Flossdorf S, Bornhäuser M, Bethge W, Fleischhauer K, Kröger N, De Wreede LC, and Christopeit M

Subjects
Humans, Transplantation, Homologous adverse effects, Germany epidemiology, Chronic Disease, Transplantation Conditioning adverse effects, Recurrence, Retrospective Studies, Hematopoietic Stem Cell Transplantation adverse effects, Graft vs Host Disease epidemiology, Graft vs Host Disease etiology
Abstract

Incidences of diseases treated with transplantation frequently peak at higher age. The contribution of age to total risk of transplantation has not been estimated amidst an aging society. We compare outcomes of 1,547 patients aged 70-79 years and 9,422 patients aged 60-69 years transplanted 1998-2018 for myeloid, lymphoid and further neoplasia in Germany. To quantify the contribution of population mortality to survival, we derive excess mortality based on a sex-, year- and agematched German population in a multistate model that incorporates relapse and graft-versus-host-disease (GvHD). Overall survival, relapse-free survival (RFS) and GvHD-free-relapse-free survival (GRFS) is inferior in patients aged 70-79 years, compared to patients aged 60-69 years, with 36% (95% Confidence Interval [CI]: 34-39%) versus 43% (41-44%), 32% (30- 35%) versus 36% (35-37%) and 23% (21-26%) versus 27% (26-28%) three years post-transplant (P<0.001). Cumulative incidences of relapse at three years are 27% (25-30%) for patients aged 70-79 versus 29% (29-30%) (60-69 years) (P=0.71), yet the difference in non-relapse mortality (NRM) (40% [38-43%] vs. 35% [34-36%] in patients aged 70-79 vs. 60-69 years) (P<0.001) translates into survival differences. Median OS of patients surviving >1 year relapse-free is 6.7 (median, 95% CI: 4.5-9.4, 70-79 years) versus 9 (8.4-10.1, 60-69 years) years since landmark. Three years after RFS of one year, excess NRM is 14% (95% CI: 12-18%) in patients aged 70-79 versus 12% [11-13%] in patients aged 60-69, while population NRM is 7% (6-7%) versus 3% (3-3%). Mortality for reasons other than relapse, GvHD, or age is as high as 27% (24-29%) and 22% (22-23%) four years after transplantation. In conclusion, survival amongst older patients is adequate after allogeneic stem cell transplantation.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results